You have access
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium
Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922
